AUS
NZ
UK
CA
USA
IND
Highlights
- US policy changes back research on rare diseases
- Australian biotech firms gain momentum
- New regulatory clarity benefits orphan drug development
Australian biotech companies focused on rare disease therapies are gaining traction following recent healthcare reforms in the United States. The One Big Beautiful Bill Act (OBBBA) has expanded provisions supporting orphan drugs — treatments developed for rare conditions affecting fewer than 200,000 people in the US.
This legislative shift is drawing attention to the sector, particularly among ASX-listed developers with Fast Track designations from the US Food and Drug Administration. While the ASX 200 primarily includes large-cap companies, these specialised biotech players outside the index are becoming more visible due to their potential relevance in rare disease markets.
Understanding the Policy Shift
Under the revised guidelines, orphan drugs treating multiple rare diseases will continue to enjoy exemptions from Medicare price negotiations. Previously, these exemptions were limited, potentially deterring further development once a product gained approval.
The OBBBA introduces key changes:
- Expanded Exemption: Drugs that address more than one rare condition remain shielded from Medicare pricing rules.
- Delayed Price Negotiations: Discussions on pricing are postponed until the drug receives approval for non-rare disease use.
- Encouragement for Multi-Indication Research: Developers are now more likely to explore broader uses of the same drug without facing early pricing restrictions.
These policy enhancements offer developers more time to market therapies, with a clearer pathway toward commercialisation.
Australian Biotechs Positioned for Impact
A number of Australian biotechnology companies are actively progressing rare disease drug development and are positioned to align with the updated US policy direction.
- Prescient Therapeutics (ASX:PTX) received Fast Track status for its T-cell lymphoma therapy, PTX-100, which is now progressing under favourable US regulatory conditions.
- Imugene (ASX:IMU) is advancing AZER-Cel, a CAR-T cell therapy targeting specific cancers, supported by FDA Fast Track status that may enable a more streamlined path through clinical stages.
- Race Oncology (ASX:RAC) secured an extension of its Orphan Drug Designation for RC220, a treatment in development for acute myeloid leukemia, which now aligns well with the OBBBA’s benefits.
Outlook for Innovation and Development
The changes in the US orphan drug policy may act as a catalyst for research and regulatory progress among biotech firms aiming to address complex rare diseases. For Australian companies, this development also enhances visibility and positions their pipelines as attractive for global partnerships and funding interest.
With these reforms encouraging deeper investment into rare disease solutions, niche biotech players on the ASX are expected to benefit from improved support structures, especially in the development of innovative therapies that meet unmet medical needs.
Frequently Asked Questions
- What is the Orphan Drug Act in the US?
The Orphan Drug Act promotes the development of treatments for rare diseases, offering incentives like market exclusivity and regulatory support. - How does the OBBBA impact Australian biotech firms?
It creates a more favourable environment for companies developing rare disease therapies by extending protection from price negotiations. - Are any ASX 200 companies involved in orphan drug development?
The highlighted companies in this article are currently outside the ASX 200, but the policy shift may increase their visibility in broader market discussions.
